18,341 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Bought by AQR Capital Management LLC

AQR Capital Management LLC acquired a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 18,341 shares of the company’s stock, valued at approximately $30,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Caribou Biosciences in the second quarter worth $52,000. Point72 DIFC Ltd boosted its holdings in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after acquiring an additional 23,995 shares during the period. XTX Topco Ltd acquired a new position in shares of Caribou Biosciences during the second quarter valued at $341,000. Hsbc Holdings PLC boosted its holdings in shares of Caribou Biosciences by 476.4% during the second quarter. Hsbc Holdings PLC now owns 80,867 shares of the company’s stock valued at $129,000 after acquiring an additional 66,838 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Caribou Biosciences during the second quarter valued at $2,432,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CRBU shares. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Tuesday, September 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Caribou Biosciences in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Caribou Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $2.00 on Friday. Caribou Biosciences, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $8.33. The stock’s 50-day moving average is $1.98 and its two-hundred day moving average is $2.50. The stock has a market cap of $180.64 million, a PE ratio of -1.38 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.04. The business had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $3.31 million. Caribou Biosciences had a negative return on equity of 34.76% and a negative net margin of 372.78%. On average, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.